As a clinical trial sponsor, being able to measure research programs with pinpoint accuracy is a valuable proposition.
As a clinical trial sponsor, being able to measure research programs with pinpoint accuracy is a valuable proposition. That's precisely what DAC Patient Recruitment Services (DAC), an Imperial company and a leader in clinical trial patient recruitment and retention, offers through its proprietary DACTracks™ technology.
"Evaluating real-time program data is essential in analyzing return on investment," said DAC Vice President of Operations Melynda Geurts. "That is why DAC created DACTracks. This active, online reporting system keeps valuable program data at our clients' fingertips."
Sponsors will enjoy 24-hour access to reports on their research sites' screenings, referrals, randomizations (projected and actual), enrollment, attrition, and more. Both site-specific and global data are available. Impact graphs map recruitment trends following the launch of specific initiatives, and charts display the number of aggregate and site-specific referrals color-coded by source. The retention page features the total number of active and non-active subjects in the study and a summary of discontinued subjects, including reasons for discontinuation.
DACTracks also provides comprehensive statistics on study website performance, including unique site visitors, page views, online pre-qualification, and web traffic sources. Regarding the latter, users will be able to discern at the click of a mouse whether web traffic originated from search engines, referring sites or direct traffic to the study website URL.
For more information about DACTracks, and to sign up for a free demonstration, visit www.imperialcrs.com/dac/dactracks or write to [email protected]
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.